Article
Behavioral Sciences
Koichi Hirata, Takao Takeshima, Fumihiko Sakai, Noboru Imai, Yasuhiko Matsumori, Yoshihisa Tatsuoka, Yotaro Numachi, Ryuji Yoshida, Cheng Peng, Daniel D. Mikol, Gabriel Paiva da Silva Lima, Sunfa Cheng
Summary: In two 24-week migraine prevention studies, erenumab demonstrated significant reduction in migraine frequency compared to placebo, with efficacy observed as early as the first 4 weeks of treatment initiation.
BRAIN AND BEHAVIOR
(2022)
Article
Clinical Neurology
Shengyuan Yu, Byung-Kun Kim, Hebo Wang, Jiying Zhou, Qi Wan, Tingmin Yu, Yajun Lian, Michal Arkuszewski, Laurent Ecochard, Shihua Wen, Fangfang Yin, Zheng Li, Wendy Su, Shuu-Jiun Wang
Summary: The DRAGON study evaluated the efficacy and safety of erenumab in Asian patients with chronic migraine. The results showed that erenumab treatment significantly reduced migraine days and improved efficacy, with a comparable safety profile to placebo.
JOURNAL OF HEADACHE AND PAIN
(2022)
Article
Pharmacology & Pharmacy
Michael L. Garelja, Tyla I. Alexander, Amy Bennie, Mhairi Nimick, Jakeb Petersen, Christopher S. Walker, Debbie L. Hay
Summary: This study demonstrates that erenumab can antagonize both CGRP and AMY(1) receptors, providing insights into the clinical profile of erenumab.
BRITISH JOURNAL OF PHARMACOLOGY
(2023)
Article
Clinical Neurology
Eleonora De Matteis, Giannapia Affaitati, Ilaria Frattale, Valeria Caponnetto, Francesca Pistoia, Maria Adele Giamberardino, Simona Sacco, Raffaele Ornello
Summary: The study evaluated early outcomes of erenumab discontinuation in migraine patients who had a continuous positive response. Results showed that most patients experienced worsening symptoms in the first 4 weeks after treatment cessation, although still lower than baseline. More than half of the patients had an early disease worsening, while others maintained their responder status after treatment completion. Further studies are needed to identify predictors of prolonged response to erenumab and determine the optimal treatment duration based on patients' characteristics.
NEUROLOGICAL SCIENCES
(2021)
Article
Clinical Neurology
Xing Wang, Qiang He, Dingke Wen, Lu Ma, Chao You
Summary: The study showed that both erenumab 70 mg and 140 mg reduced monthly migraine days in adult patients with migraine, with erenumab 140 mg demonstrating significantly better efficacy than 70 mg. Neither dosage was associated with increased risk of treatment-emergent adverse events. Future randomized controlled trials with larger sample sizes are needed to validate these findings.
NEUROLOGICAL SCIENCES
(2022)
Article
Neurosciences
Raffaele Ornello, Ilaria Frattale, Valeria Caponnetto, Eleonora De Matteis, Francesca Pistoia, Simona Sacco
Summary: The study aimed to evaluate differences in menstrual vs non-menstrual headache in women with chronic migraine treated with erenumab. The results showed that migraine was more frequent during menstrual days even in women treated with erenumab. Additionally, in non-responders, headache days with >= 2 acute medications were higher during menstrual days compared to premenstrual or non-menstrual days.
Article
Clinical Neurology
Bo Hu, Gang Li, Xiaohong Li, Shan Wu, Tingmin Yu, Xiang Li, Hongru Zhao, Zhihua Jia, Junpeng Zhuang, Shengyuan Yu
Summary: This study evaluated the efficacy and safety of galcanezumab in patients with episodic migraine from China, India, and Russia. The results showed that monthly galcanezumab treatment significantly reduced migraine headache days and improved patients' quality of life, with good tolerability.
JOURNAL OF HEADACHE AND PAIN
(2022)
Article
Clinical Neurology
Fumihiko Sakai, Norihiro Suzuki, Byung-Kun Kim, Yoshihisa Tatsuoka, Noboru Imai, Xiaoping Ning, Miki Ishida, Kaori Nagano, Katsuhiro Iba, Hiroyuki Kondo, Nobuyuki Koga
Summary: The study evaluated the efficacy and safety of fremanezumab in Japanese and Korean patients with episodic migraine. Results showed that fremanezumab significantly reduced the average number of migraine days per month and increased the proportion of patients reaching at least a 50% reduction in migraine days compared to placebo, with similar effectiveness and safety as previously reported populations.
Article
Clinical Neurology
Dionne M. Hines, Shweta Shah, Jasjit K. Multani, Rolin L. Wade, Dawn C. Buse, Mark Bensink
Summary: This retrospective study aimed to describe patient characteristics, adherence, and treatment patterns of adult migraine patients in the United States prescribed erenumab. The majority of patients started with an initial erenumab dose of 70 mg and most maintained this dose during follow-up. Adherence to erenumab was higher compared to traditional oral prophylactic migraine therapies, but overall adherence was still suboptimal. The decrease in use of acute and preventive prescription medications following initiation of erenumab suggests its effectiveness in the real-world setting.
Article
Clinical Neurology
Richard B. Lipton, Dawn C. Buse, Claire H. Sandoe, Janet H. Ford, Austin L. Hand, Jakub P. Jedynak, Martha D. Port, Holland C. Detke
Summary: Objective: To evaluate the changes in interictal burden in patients with episodic or chronic migraine when treated with galcanezumab versus placebo. The study found that galcanezumab significantly reduced interictal burden, indicating its efficacy in managing migraine between attacks.
Review
Clinical Neurology
Stewart J. Tepper, Huma U. Sheikh, Carrie O. Dougherty, Stephanie J. Nahas, Paul K. Winner, Ananda Krishna Karanam, Andrew M. Blumenfeld, Ahmad Abdrabboh, Soeren Rasmussen, Jamie L. Weiss, Jessica Ailani
Summary: This article evaluates the therapeutic and tolerability differences between Erenumab 70 mg and 140 mg based on evidence from published literature. The results indicate that some patients may benefit from a dosage of 140 mg, especially those with difficult-to-treat disease and prior treatment failures. Cumulative data support a therapeutic gain with an increase from Erenumab 70 mg to 140 mg and provide a rationale for initiating 140 mg in selected patients.
Article
Clinical Neurology
Takao Takeshima, Fumihiko Sakai, Koichi Hirata, Noboru Imai, Yasuhiko Matsumori, Ryuji Yoshida, Cheng Peng, Sunfa Cheng, Daniel D. Mikol
Summary: Erenumab demonstrated favorable efficacy and safety in Japanese patients with episodic or chronic migraine. The study showed a significant reduction in monthly migraine days with erenumab treatment, with a lower incidence of adverse events compared to placebo.
Article
Clinical Neurology
Piero Barbanti, Cinzia Aurilia, Gabriella Egeo, Luisa Fofi, Sabina Cevoli, Bruno Colombo, Massimo Filippi, Fabio Frediani, Francesco Bono, Licia Grazzi, Antonio Salerno, Bruno Mercuri, Antonio Carnevale, Claudia Altamura, Fabrizio Vernieri
Summary: Erenumab 70 mg is effective, safe, and well tolerated in real life. Easily obtainable clinical features might be of help in predicting patient's responsiveness.
Article
Clinical Neurology
Lucas Hendrik Overeem, Kristin Sophie Lange, Mira Pauline Fitzek, Anke Siebert, Maureen Steinicke, Paul Triller, Ja Bin Hong, Uwe Reuter, Bianca Raffaelli
Summary: The study aims to assess the efficacy of erenumab in patients who have previously failed a CGRP ligand mAb. The results showed that switching to erenumab in non-responders to a CGRP ligand mAb might be beneficial in a subgroup of resistant patients, with increasing responder rates after 6 months of treatment.
FRONTIERS IN NEUROLOGY
(2023)
Article
Clinical Neurology
Umberto Pensato, Carlo Baraldi, Valentina Favoni, Maria Michela Cainazzo, Paola Torelli, Pietro Querzani, Alessia Pascazio, Davide Mascarella, Eleonora Matteo, Simone Quintana, Gian Maria Asioli, Pietro Cortelli, Giulia Pierangeli, Simona Guerzoni, Sabina Cevoli
Summary: The study found that erenumab significantly reduced migraine frequency and pain medication intake in refractory chronic migraine patients with medication overuse headache. After 3 months, 51% of patients experienced a reduction of at least 50% in monthly headache days, with 20% experiencing a reduction of at least 75%. Allodynia was identified as a negative predictive factor for erenumab response, while 64% of patients clinically converted to episodic migraine without medication overuse.
NEUROLOGICAL SCIENCES
(2022)
Article
Clinical Neurology
Yu-Chien Tsao, Shuu-Jiun Wang, Chia-Lin Hsu, Yen-Feng Wang, Jong-Ling Fuh, Shih-Pin Chen, Cathy Shen-Jang Fann
Summary: This study identified two novel loci, rs10493859 in TGFBR3 and rs13312779 in FGF23, associated with self-reported headache in Asian populations. Gene enrichment analysis indicated that these genes were significantly enriched in artery and adipose tissue. These results suggest that vascular dysfunction may play a role in the pathogenesis of self-reported headache in Asians.
Article
Clinical Neurology
Po-Tso Lin, Yen-Feng Wang, Jong-Ling Fuh, Jiing-Feng Lirng, Yu-Hsiang Ling, Shih-Pin Chen, Shuu-Jiun Wang
Summary: This study successfully differentiated types of headaches associated with sexual activity and identified potential prognostic factors through a detailed clinical and radiological diagnostic algorithm.
Article
Clinical Neurology
Shu-Ting Chen, Jr-Wei Wu, Yen-Feng Wang, Jiing-Feng Lirng, Shu-Shya Hseu, Shuu-Jiun Wang
Summary: The sequence of brain magnetic resonance imaging findings in spontaneous intracranial hypotension depends on disease duration, with high incidence of venous distension sign and significant increases in diffuse pachymeningeal enhancement, severe midbrain-pons deformity, and subdural fluid collection. Patients with shorter onset-neuroimaging intervals are less likely to have neuroimaging scores >= 5, indicating the importance of considering the onset-neuroimaging interval when using neuroimaging findings for diagnostic purposes.
Review
Clinical Neurology
Kuan-Po Peng, Shuu-Jiun Wang
Summary: This review focuses on the progress of NDPH research in recent years, including the discovery of new triggers and mimics, the association with cranial and extracranial pathologies, findings from clinical studies, and the lack of effective treatment options. Overall, there is still a need for better understanding of NDPH and the development of targeted therapies.
CURRENT PAIN AND HEADACHE REPORTS
(2022)
Article
Anesthesiology
Li-Ling Hope Pan, Wei-Ta Chen, Yen-Feng Wang, Shih-Pin Chen, Kuan-Lin Lai, Hung-Yu Liu, Fu-Jung Hsiao, Shuu-Jiun Wang
Summary: This study explored the association between cortical oscillations and treatment outcome in patients with chronic migraine. The findings suggest that nonresponsive patients exhibited elevated occipital alpha activity, and changes in migraine attack frequency were associated with baseline occipital alpha power. The study provides insights for developing personalized migraine treatment plans.
Article
Environmental Sciences
Chen-Huan Chen, Shuu-Jiun Wang, Wan-Yu Yeh, Chung-Li Wu, Yong A. Wang, Cheng-Feng Chen, Ying-Ying Yang, William J. Huang, Kwan-Yee Chan, Chi-Wan Lai, Ging-Long Wang, Hao-Min Cheng
Summary: This study rigorously compared the effectiveness of a new integrated clinical clerkship program with the conventional subspecialty-based rotations at a tertiary teaching hospital. The results showed that students in the integrated clerkship program had higher scores in patient-practitioner orientation and professionalism in clinical teaching environment, compared to the comparison group.
INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH
(2022)
Review
Clinical Neurology
Li-Ling Hope Pan, Rolf-Detlef Treede, Shuu-Jiun Wang
Summary: The review found inconclusive changes to MPT in migraine patients, with the importance of considering measurement methods and well-defined migraine phases for future studies.
FRONTIERS IN NEUROLOGY
(2022)
Article
Clinical Neurology
Yen-Feng Wang, Yi-Chu Liao, Yi-Shiang Tzeng, Shih-Pin Chen, Jiing-Feng Lirng, Jong-Ling Fuh, Wei-Ta Chen, Kuan-Lin Lai, Yi-Chung Lee, Shuu-Jiun Wang
Summary: The NOTCH3 p.R544C variant is not associated with the risk or clinical manifestations of migraine. However, patients with the p.R544C variant are less likely to have pulsatile headaches and more likely to have white matter damage in the external capsule and anterior temporal lobe.
Article
Clinical Neurology
Li-Ling Hope Pan, Yen-Feng Wang, Yu-Hsiang Ling, Kuan-Lin Lai, Shih-Pin Chen, Wei-Ta Chen, Rolf-Detlef Treede, Shuu-Jiun Wang
Summary: The study found that chronic migraine patients generally had higher sensitivity compared to healthy controls, and preventive treatment with flunarizine is particularly suitable for chronic migraine patients with relatively normal sensitivity to mechanical or heat pain.
Review
Clinical Neurology
Chia-Kuang Tsai, Chia-Lin Tsai, Guan-Yu Lin, Fu-Chi Yang, Shuu-Jiun Wang
Summary: This review provides an update on the sex differences in chronic migraine (CM) and focuses on clinical characteristics, pathophysiology, and treatments. Female CM patients experience higher levels of headache-related disability, and sex hormones contribute to the sexually dimorphic characteristics and prevalence of migraine in both men and women.
CURRENT PAIN AND HEADACHE REPORTS
(2022)
Article
Clinical Neurology
Yi-Hsien Tu, Yen-Feng Wang, Hsiangkuo Yuan, Shih-Pin Chen, Yi-Shiang Tzeng, Wei-Ta Chen, Kuan-Lin Lai, Yu-Hsiang Ling, Shuu-Jiun Wang
Summary: This study investigated the distribution, clinical associations, and treatment responses for the most bothersome symptoms of migraine in a large sample of patients in Taiwan. Nausea was found to be the most common most bothersome symptom, followed by phonophobia and photophobia. The response rates to previous acute treatments for different most bothersome symptoms were similar.
Article
Clinical Neurology
Mei-Ling Sharon Tai, Anand Raj Silveraju, Han Lim Chin, Elsie Sze Ying Liaw, Lay Sim Ong, Wan Zhen Goh, Jun Kit Khoo, Ahmad Ihsan Abu Bakar, Sanjiv Mahadeva
Summary: The study aimed to evaluate the types of personality traits among patients with migraine and tension-type headache (TTH), and investigate if coexisting dyspepsia affected these traits. The results showed that headache with dyspepsia was associated with higher neuroticism, especially in TTH patients with dyspepsia compared to those without dyspepsia.
Meeting Abstract
Clinical Neurology
A. M. Dy Closas, A. H. Tan, K. J. Goh, J. P. Schee, M. H. See, S. M. L. Tai, S. Y. Lim
MOVEMENT DISORDERS
(2023)
Meeting Abstract
Clinical Neurology
Shuu-Jiun Wang, Artemio A. Roxas, Bibiana Saravia, Byung-kun Kim, Debashish Chowdhury, Naji Riachi, Mei-Ling Sharon Tai, Surat Tanprawate, Tai Ngoc Tran, Yi Jing Zhao, Gabriel Paiva da Silva Lima, Shaloo Pandhi, Shihua Wen, Subhayan Mondal, Laurent Ecochard, Michal Arkuszewski
Meeting Abstract
Clinical Neurology
Shuu-Jiun Wang, Artemio A. Roxas, Bibiana Saravia, Byung-Kun Kim, Debashish Chowdhury, Naji Riachi, Mei-Ling S. Tai, Surat Tanprawate, Tai T. Ngoc, Yi Jing J. Zhao, Wendy Su, Shihua Wen, Subhayan Mondal, Laurent Ecochard, Michal Arkuszewski, Mahan Chehrenama